Chemexpress(SH:688131) Sou Hu Cai Jing·2025-06-02 02:11Core Viewpoint - The article discusses the recent shareholding changes of Su Xin Fund and Zhen Jin Investment in Hao Yuan Pharmaceutical, highlighting their reduction in shareholding and the company's financial performance expectations for 2024 [1][3][4]. Shareholding Changes - Su Xin Fund's shareholding has decreased to 10.548 million shares, representing 5% of the company, thus no longer being a major shareholder [1] - Su Xin Fund plans to reduce up to 6.3288 million shares, accounting for 3% of the total share capital, from March 18 to June 17 [2] - Zhen Jin Investment has completed its reduction of 3.1955 million shares, which is 1.51% of the total share capital, from February 28 to May 22 [2][3] Financial Performance Expectations - Hao Yuan Pharmaceutical anticipates a revenue of CNY 2.1 billion to CNY 2.3 billion for 2024, reflecting a year-on-year growth of 11.70% to 22.34% [4] - The expected net profit attributable to shareholders is projected to be between CNY 185 million and CNY 210 million, indicating a growth of 45.16% to 64.77% [4] - The company attributes its profit growth to the strong performance of its high-margin life science reagent business, which has seen an increase in revenue share compared to 2023 [4] Market Performance - As of May 30, Hao Yuan Pharmaceutical's stock price increased by 15.26% to CNY 44.10 per share, with a market capitalization of CNY 9.303 billion, and has risen over 107% in the past year [5] - The stock's trading volume on the last trading day was 13.5295 million shares, with a turnover rate of 6.56% [6]